<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03876119</url>
  </required_header>
  <id_info>
    <org_study_id>CHOICE</org_study_id>
    <nct_id>NCT03876119</nct_id>
  </id_info>
  <brief_title>Intraarterial Alteplase Versus Placebo After Mechanical Thrombectomy</brief_title>
  <acronym>CHOICE</acronym>
  <official_title>CHemical OptImization of Cerebral Embolectomy in Patients With Acute Stroke Treated With Mechanical Thrombectomy (CHOICE) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundació La Marató de TV3</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, randomized, placebo-controlled, double blind, phase 2b trial of acute stroke
      patients treated with mechanical thrombectomy (MT), in which two therapies are compared:
      rt-PA or placebo. Allocation at each center will account for 1 stratum: use of alteplase (yes
      vs. no) before MT. Subjects will be followed up to 90 days post-randomization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to evaluate whether rt-PA is safe and efficient as an add-on to
      mechanical thrombectomy (MT) in patients with acute ischemic stroke and complete or
      near-complete recanalization of a proximal vessel occlusion but partial brain reperfusion on
      cerebral angiogram &gt;50% and &lt;91% brain reperfusion on cerebral angiography (corresponding to
      mTICI score 2b). The study is a multicenter, randomized, placebo-controlled, double blind,
      phase 2b trial of acute stroke patients treated with MT, in which two therapies are compared:
      rt-PA or placebo. Allocation at each center will account for 1 stratum: use of alteplase (yes
      vs. no) before MT. Subjects will be followed up to 90 days post-randomization. Patients will
      be enrolled in the angiosuit by interventionalists or neurologists once a mTICI 2b is
      confirmed at the end of a routinely performed endovascular procedure. The primary outcome is
      the proportion of patients with an improved mTICI score ten (10) minutes after the end of the
      experimental study treatment. A sample size of 100 patients per treatment arm in a 1:1
      allocation will have &gt;95% statistical power for the primary outcome (5% of improved TICI
      score control vs 60% in experimental) for a two-sided 5% alpha, taken into account a 5% of
      the sample lost to follow up. This sample size will also guarantee around 80% power for most
      of the secondary outcomes with at least 90 valid patients per arm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomized, placebo-controlled, double blind, phase 2b trial of acute stroke patients treated with MT, in which two therapies are compared: rt-PA or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The solutions of alteplase or placebo are limpid, transparent and colorless. Alteplase (Actilyse 10 mg powder and solvent for solution for injection and infusion) and placebo will be provided in kind by Boëhringer Ingelheim. The secondary conditioning of the investigation treatment will be performed by Alcura Health Spain S.A.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of increased modified Treatment in Cerebral Ischemia (mTICI) score.</measure>
    <time_frame>Ten (10) minutes after the end of study treatment.</time_frame>
    <description>The primary outcome will be the proportion of patients with an increased modified Treatment in Cerebral Ischemia (mTICI) score ten (10) minutes after the end of study treatment. The mTICI scale distinguishes no perfusion (mTICI grade 0), minimal flow past the occlusion but no perfusion (mTICI grade 1), partial reperfusion of less than half of the TDT (mTICI grade 2a), partial reperfusion of more than half of the TDT (mTICI grade 2b), and complete reperfusion without any flow defects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Shift analysis of the 90-day modified Rankin Scale (mRS).</measure>
    <time_frame>Day 90 after treatment.</time_frame>
    <description>The shift analysis of the modified Rankin Scale (mRS) evaluated as an ordinal scale at day 90. The mRS is a global disability scale with a range from 0, indicating no residual symptoms, to 5, for patients who are bedridden and require constant care, and 6, for patients who are dead.The mRS at 90 days will be analyzed using a proportional odds model (POM) that combine into single worst rank the last two categories (5: severe incapacity and 6: death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct expansion ratio.</measure>
    <time_frame>24 hours after treatment.</time_frame>
    <description>Infarct Expansion Ratio on DWI-MRI (continuous variable), at 24h of stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of excellent outcome at day 90.</measure>
    <time_frame>Day 90 after treatment.</time_frame>
    <description>Proportion of patients with excellent outcome at day 90, defined as a modified Rankin Scale (mRS) 0-1. The mRS is a global disability scale with a range from 0, indicating no residual symptoms, to 5, for patients who are bedridden and require constant care, and 6, for patients who are dead.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of infarct expansion at 24 hours.</measure>
    <time_frame>24 hours after treatment.</time_frame>
    <description>Proportion of patients with/without infarct expansion (dichotomous variable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final infarct volume.</measure>
    <time_frame>24 hours after treatment.</time_frame>
    <description>Infarction Volume on Diffusion Weighted Imaging (Magnetic Resonance Imaging) at 24h of stroke onset</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of good clinical outcome at day 90.</measure>
    <time_frame>Day 90 after treatment.</time_frame>
    <description>Good clinical outcome at day 90, defined as a modified Rankin Scale (mRS) 0-2. The mRS is a global disability scale with a range from 0, indicating no residual symptoms, to 5, for patients who are bedridden and require constant care, and 6, for patients who are dead.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Barthel Scale score higher or equal to 95 at day 90.</measure>
    <time_frame>Day 90 after treatment.</time_frame>
    <description>Barthel Scale score of 95 to 100, at day 90. The Barthel scale is an ordinal scale used to measure performance in activities of daily living (ADL). Each performance item is rated on this scale with a given number of points assigned to each level or ranking where higher scores indicate better performance.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of ischemic worsening within 72 hours of stroke onset.</measure>
    <time_frame>72 hours after stroke onset.</time_frame>
    <description>Ischemic worsening (&gt; 4 points in the NIHSS score) within 72 hours of stroke onset not attributable to stroke recurrence.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in quality of life at day 90.</measure>
    <time_frame>Day 90 after treatment.</time_frame>
    <description>Quality of life measured with the EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D-3L) at 90 day. The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>Intraarterial alteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients within this arm will be given a 30 minutes intraarterial (IA) infusion of alteplase (Actylise®) at a drug concentration of 0.5mg/ml. At 20 minutes of IA treatment onset, the infusion will be temporarily stopped and restarted until completion of the 30 minutes infusion only if the mTICI 2b score has not improved on control angiography. Study drug will be prepared according to the following steps: 1. Dilute 3 vials of 10 mgs (alteplase) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml; 2. Dilute this solution in 30 cc of normal saline, to attain a 60 cc solution at a concentration of 0.5mg/ml; 3. Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225) multiplied by 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo will consist of a lyophilized white powder containing 0.2 mol/L arginine phosphate, 0.01% polysorbate 80, and pH 7.4 after reconstitution. Study drug will be prepared according to the following steps: 1. Dilute 3 vials of 10 mgs (placebo) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml; 2. Dilute this solution in 30 cc of normal saline, to attain a 60 cc solution at a concentration of 0.5mg/ml; 3. Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225) multiplied by 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intraarterial alteplase</intervention_name>
    <description>See arm/group descriptions.</description>
    <arm_group_label>Intraarterial alteplase</arm_group_label>
    <other_name>Intraarterial alteplaserecombinant tissue plasminogen activator (rTPA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>See arm/group descriptions.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with symptomatic large vessel occlusion (LVO) in the anterior, middle or
             posterior cerebral artery treated with MT resulting in a mTICI score 2b at end of the
             procedure.

          2. Estimated delay to onset of rescue intraarterial rt-PA administration &lt;24 hours from
             symptom onset, defined as the point in time the patient was last seen well.

          3. No significant pre-stroke functional disability (modified Rankin scale 0-1).

          4. Age ≥18.

          5. ASPECTS &gt;6 on non-contrast CT (NCCT) scan if symptoms lasting &lt;4.5 hours or ASPECTS &gt;6
             on CT-Perfusion (CTP) if symptoms &gt;4.5 &lt;24 hours. In both cases, ASPECTS is obtained
             within &lt;75 minutes of the onset of mechanical thrombectomy.

          6. Informed consent obtained from patient or acceptable patient surrogate.

        Exclusion Criteria:

          1. NIHSS score on admission &gt;25.

          2. Contraindication to IV t‐PA as per local national guidelines (except time to therapy).

          3. Use of carotid artery stents during the endovascular procedure requiring dual
             antiplatelet therapy.

          4. Female who is pregnant or lactating or has a positive pregnancy test at time of
             admission.

          5. Current participation in another investigation drug or device treatment study (except
             observational study i.e.: RACECAT).

          6. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency.

          7. Known coagulopathy, INR &gt; 1.7 or use of novel anticoagulants &lt; 12h from symptom onset.

          8. Platelets &lt; 50,000.

          9. Renal Failure as defined by a serum creatinine &gt; 3.0 mg/dl (or 265.2 μmol/l) or
             glomerular Filtration Rate [GFR] &lt; 30.

         10. Subject who requires hemodialysis or peritoneal dialysis, or who have a
             contraindication to an angiogram for whatever reason.

         11. Any hemorrhage on CT/MRI.

         12. Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI
             scan is normal.

         13. Suspicion of aortic dissection.

         14. Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol.

         15. History of life threatening allergy (more than rash) to contrast medium.

         16. SBP &gt;185 mmHg or DBP &gt;110 mmHg refractory to treatment.

         17. Serious, advanced, terminal illness with anticipated life expectancy &lt; 6 months.

         18. Pre-existing neurological or psychiatric disease that would confound evaluation.

         19. Presumed vasculitis or septic embolization.

         20. Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor
             from overseas).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angel Chamorro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Comprehensive Stroke Center, Hospital Clinic Barcelona.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arturo Renú, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Stroke Center, Hospital Clinic Barcelona.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marián Muchada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Vall d'Hebrón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisa Cuadrado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Ramos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pol Camps, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pere Cardona, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martha Vargas, PhD</last_name>
    <phone>0034-93 227 54 00</phone>
    <phone_ext>2118</phone_ext>
    <email>mvargas@clinic.ub.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sergi Amaro, MD</last_name>
    <phone>0034-93 227 54 00</phone>
    <phone_ext>2118</phone_ext>
    <email>samaro@clinic.ub.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arturo Renú, MD</last_name>
      <phone>932275414</phone>
      <email>arenu@clinic.ub.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Cuadrado, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan M Fábregas, MD</last_name>
      <email>jmarti@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Germans Trias i Pujol Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Ramos, MD</last_name>
      <email>annaramosp@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pere Cardona, MD</last_name>
      <email>pcardonap@bellvitgehospital.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marian Muchada, MD</last_name>
      <email>muchadamarian@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Chamorro Á, Blasco J, López A, Amaro S, Román LS, Llull L, Renú A, Rudilosso S, Laredo C, Obach V, Urra X, Planas AM, Leira EC, Macho J. Complete reperfusion is required for maximal benefits of mechanical thrombectomy in stroke patients. Sci Rep. 2017 Sep 14;7(1):11636. doi: 10.1038/s41598-017-11946-y.</citation>
    <PMID>28912596</PMID>
  </reference>
  <reference>
    <citation>Dávalos A, Cobo E, Molina CA, Chamorro A, de Miquel MA, Román LS, Serena J, López-Cancio E, Ribó M, Millán M, Urra X, Cardona P, Tomasello A, Castaño C, Blasco J, Aja L, Rubiera M, Gomis M, Renú A, Lara B, Martí-Fàbregas J, Jankowitz B, Cerdà N, Jovin TG; REVASCAT Trial Investigators. Safety and efficacy of thrombectomy in acute ischaemic stroke (REVASCAT): 1-year follow-up of a randomised open-label trial. Lancet Neurol. 2017 May;16(5):369-376. doi: 10.1016/S1474-4422(17)30047-9. Epub 2017 Mar 16.</citation>
    <PMID>28318984</PMID>
  </reference>
  <reference>
    <citation>Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, San Román L, Serena J, Abilleira S, Ribó M, Millán M, Urra X, Cardona P, López-Cancio E, Tomasello A, Castaño C, Blasco J, Aja L, Dorado L, Quesada H, Rubiera M, Hernandez-Pérez M, Goyal M, Demchuk AM, von Kummer R, Gallofré M, Dávalos A; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015 Jun 11;372(24):2296-306. doi: 10.1056/NEJMoa1503780. Epub 2015 Apr 17.</citation>
    <PMID>25882510</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>March 15, 2019</last_update_submitted>
  <last_update_submitted_qc>March 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Angel Chamorro, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Director, Comprehensive Stroke Center, Hospital Clinic Barcelona. Professor of Neurology, University of Barcelona.</investigator_title>
  </responsible_party>
  <keyword>Mechanical Thrombectomy</keyword>
  <keyword>Recanalization</keyword>
  <keyword>Reperfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Plasminogen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified individual participant data on outcome measures will be published along with the main results of the trial.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The data will become available after publication of main study results.</ipd_time_frame>
    <ipd_access_criteria>The IPD will be available from the Sponsor of the trial on reasonable request.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT03876119/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

